Equities analysts expect Aptinyx Inc (NASDAQ:APTX) to announce ($0.50) earnings per share for the current quarter, according to Zacks. Two analysts have made estimates for Aptinyx’s earnings, with the highest EPS estimate coming in at ($0.47) and the lowest estimate coming in at ($0.54). The business is scheduled to announce its next quarterly earnings results on Tuesday, February 12th.
According to Zacks, analysts expect that Aptinyx will report full-year earnings of ($2.55) per share for the current financial year, with EPS estimates ranging from ($2.74) to ($2.26). For the next fiscal year, analysts expect that the company will report earnings of ($2.55) per share, with EPS estimates ranging from ($2.68) to ($2.39). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Aptinyx.
Aptinyx (NASDAQ:APTX) last posted its quarterly earnings data on Tuesday, November 13th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($1.01) by $0.58. The company had revenue of $0.94 million during the quarter, compared to the consensus estimate of $1.10 million.
Separately, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Aptinyx in a research report on Monday, December 3rd. Five investment analysts have rated the stock with a buy rating, Aptinyx has a consensus rating of “Buy” and a consensus target price of $34.25.
APTX opened at $17.93 on Friday. Aptinyx has a 12 month low of $15.01 and a 12 month high of $32.25.
A number of institutional investors and hedge funds have recently bought and sold shares of APTX. Legal & General Group Plc bought a new stake in Aptinyx during the 3rd quarter worth about $58,000. Strs Ohio bought a new stake in shares of Aptinyx in the 3rd quarter valued at about $110,000. Point72 Hong Kong Ltd bought a new stake in shares of Aptinyx in the 2nd quarter valued at about $134,000. Wells Fargo & Company MN bought a new stake in shares of Aptinyx in the 3rd quarter valued at about $185,000. Finally, American International Group Inc. bought a new stake in shares of Aptinyx in the 3rd quarter valued at about $256,000. 64.76% of the stock is currently owned by institutional investors and hedge funds.
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Further Reading: Different Types of Derivatives
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.